Presentation

Sedana Medical is a medtech and pharmaceutical company founded in 2005. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Recent highlights
In Q2, net sales totalled 27M SEK (-32%) (-34% at constant exchange rates), a consequence of a significant decline in ventilated patients in intensive care units.
In January, the National Institute for Health and Care Excellence (NICE) issued positive guidance on Sedaconda ACD as a cost-saving option for delivering inhaled sedation in intensive care as an alternative to intravenous sedation. In April, the company announced enrolment of first patient in the Ph3 pivotal trials in the US, aiming to confirm the efficacy and safety of inhaled isoflurane, delivered via the Sedaconda ACD, for the sedation of adult mechanically ventilated ICU patients, in comparison to intravenous infusion of propofol.

Outlook
Following the initiation of the Ph3 pivotal trials in the US, the company will progress patient recruitment and aim for NDA approval in 2024. Following Sedaconda launch in several EU markets, the company will also progress the pricing and reimbursement processes and expect launches in all major markets by the end of 2022.